<?xml version="1.0" encoding="UTF-8"?>
<p id="Par20">Thus, the initial clinical entry product profile would be a liquid drug product at a moderate concentration, stored cold or frozen. The preformulation screen would evaluate only proven formulations and excipients. The container-closure materials should likewise be stock items. Establishing long-term (multi-year) stability for early clinical material would not be required; resupply with new batches of drug substance and/or rapid consumption of drug product in the clinic combine to limit any risk of poor stability of the formulated drug product.</p>
